Home / Health / New Pill Outperforms Injectable Weight-Loss Drugs
New Pill Outperforms Injectable Weight-Loss Drugs
25 Mar
Summary
- New daily pill orforglipron proves more effective than current oral options.
- Orforglipron shows superior blood sugar reduction and greater weight loss.
- Higher gastrointestinal side effects noted with orforglipron compared to semaglutide.
A new daily oral medication, orforglipron, is emerging as a significant contender in the weight-loss drug market, showing greater efficacy than current oral semaglutide. Developed by Eli Lilly, this small-molecule drug aims to overcome the limitations of injectable GLP-1 medications.
A recent 52-week phase 3 clinical trial involving 1,698 adults with type 2 diabetes across six countries highlighted orforglipron's effectiveness. Participants taking orforglipron experienced a superior reduction in HbA1c levels and achieved more substantial weight loss compared to those on oral semaglutide.
However, the trial also noted a higher incidence of gastrointestinal side effects, such as nausea and vomiting, among orforglipron users. This led to a greater percentage of participants discontinuing treatment due to adverse effects compared to the semaglutide group.
Orforglipron's small-molecule structure makes it potentially cheaper and simpler to manufacture than peptide-based drugs. Like oral semaglutide, it requires no refrigeration, offering a logistical advantage over injectables, especially for low- and middle-income countries.
Further trials are underway for orforglipron in patients with obesity but without diabetes. The drug's long-term adherence will be crucial, influenced by both its efficacy and tolerability.
